Evidence map›Paper›PMID 39259342›Full record

ArticleMolecular biology reports2024

Cylindromatosis lysine 63 deubiquitinase (CYLD) suppress TLR3-mediated CCL5 expression in human renal proximal tubular epithelial cells.

Mayuki Tachizaki, Yuri Kobori, Shogo Kawaguchi, Kazuhiko Seya, Hiroshi Tanaka, Tadaatsu Imaizumi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Inflammatory factors collaboratively linkFrontiers in immunology · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mayuki TachizakiDepartment of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu- cho, Hirosaki, Aomori, 036-8562, Japan. mayuki1124@hirosaki-u.ac.jp.ORCID https://orcid.org/0009-0002-7343-9121
Yuri KoboriDepartment of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Shogo KawaguchiDepartment of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu- cho, Hirosaki, Aomori, 036-8562, Japan.
Kazuhiko SeyaDepartment of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu- cho, Hirosaki, Aomori, 036-8562, Japan.
Hiroshi TanakaDepartment of School Health Science, Hirosaki University Faculty of Education, 1 Bunkyo-cho, Hirosaki, Aomori, 036-8560, Japan.
Tadaatsu ImaizumiDepartment of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu- cho, Hirosaki, Aomori, 036-8562, Japan.

Funding

JSPS KAKENHI 22K07862
6 · The paper itself

Abstract

backgroundOne of the causes of tubulointerstitial nephritis is viral infection, with innate immune responses affecting its pathogenesis. Toll-like receptor 3 (TLR3) recognizes viral infections and acts antivirally by activating signaling to produce inflammatory cytokines/chemokines, including C-C motif chemokine ligand 5 (CCL5) and interferon-β (IFN-β). Although cylindromatosis lysine 63 deubiquitinase (CYLD) is known to be associated with tubulointerstitial nephritis and renal function, its role in the antiviral innate immune response in tubular epithelial cells remains unknown. In this study, we investigated the association between CYLD and TLR3-mediated CCL5 production in cultured human renal proximal tubular epithelial cells (hRPTECs). METHODS AND

resultsPolyinosinic-polycytidylic acid (poly IC), a synthetic TLR3 ligand, was used to stimulate hRPTECs. mRNA expression was measured using reverse transcription-quantitative polymerase chain reaction. Protein expression was assayed using western blotting or an enzyme-linked immunosorbent assay. Knockdown of IFN-β, nuclear factor-kappa B (NF-κB) p65, and CYLD was performed by transfecting cells with specific small interfering RNAs. The intracellular localization of CYLD in hRPTECs was analyzed using immunofluorescence. Poly IC induced CCL5 expression in a time- and concentration-dependent manner, and knockdown of either IFN-β or p65 reduced poly IC-induced CCL5 expression. CYLD knockdown increased the poly IC-induced CCL5, phosphorylated IκB kinase α/β (IKK complex), and phosphorylated p65 expression. The CYLD protein was localized in the cytoplasm, and poly IC did not alter its expression.

conclusionCYLD may prevent excessive inflammation due to an antiviral innate immune response by suppressing IKK complex and NF-κB activation downstream of TLR3 in hRPTECs.

Indexed as

Chemokine CCL5Deubiquitinating Enzyme CYLDEpithelial CellsKidney Tubules, ProximalPoly I-CToll-Like Receptor 3Cell LineHumansImmunity, InnateInterferon-betaNF-kappa BSignal TransductionTranscription Factor RelACCL5 protein, humanChemokine CCL5CYLD protein, humanDeubiquitinating Enzyme CYLDInterferon-betaNF-kappa BPoly I-CTLR3 protein, humanToll-Like Receptor 3Transcription Factor RelAC-C motif chemokine ligand 5Cylindromatosis lysine 63 deubiquitinaseHuman renal proximal tubular epithelial cellInterferon-βToll-like receptor 3

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.